Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Leases: 2022-2025

Historic Operating Leases for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to $1.1 million.

  • Dianthus Therapeutics' Operating Leases was N/A to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2024, which is 597.02% up from last year.
  • Dianthus Therapeutics' Operating Leases amounted to $1.1 million in Q3 2025, which was down 4.56% from $1.1 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Operating Leases high stood at $32.4 million for Q1 2022, and its period low was $30,000 during Q2 2024.
  • Its 3-year average for Operating Leases is $635,000, with a median of $662,500 in 2023.
  • As far as peak fluctuations go, Dianthus Therapeutics' Operating Leases crashed by 99.05% in 2023, and later soared by 3,630.00% in 2025.
  • Over the past 4 years, Dianthus Therapeutics' Operating Leases (Quarterly) stood at $438,000 in 2022, then slumped by 61.64% to $168,000 in 2023, then surged by 597.02% to $1.2 million in 2024, then soared by 3,630.00% to $1.1 million in 2025.
  • Its Operating Leases stands at $1.1 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.2 million for Q1 2025.